LUNAM Université - Ingénierie de la vectorisation particulaire in Macro et nanomédecines biomimétiques, F-49933 Angers, France.
Curr Opin Pharmacol. 2012 Aug;12(4):420-6. doi: 10.1016/j.coph.2012.04.006. Epub 2012 May 18.
Since the serependitous discovery of the cisplatin antiproliferative activity, many efforts have focused on the design of potent metal-based drugs for oncology therapies. A large number of these complexes have been evaluated in vitro and in vivo and some have reached clinical trials. However, while metallodrug chemistry has developed to an advanced level, these emerging therapeutics have encountered new hurdles including poor water solubility and pharmacological deficiencies. Today, solutions to overcome these issues do not lie in synthesizing new anticancer drugs but in finding suitable drug delivery strategies. Over the past decades, various delivery systems have been developed including prodrug, ligand design and nanocarriers aimed at enhancing the performance profile of these novel metallodrugs.
自从顺铂的抗增殖活性被偶然发现以来，许多研究都集中在设计用于肿瘤治疗的有效金属基药物上。大量这些配合物已经在体外和体内进行了评估，其中一些已经进入临床试验。然而，尽管金属药物化学已经发展到了很高的水平，这些新兴的治疗方法还是遇到了新的障碍，包括较差的水溶性和药理学缺陷。如今，克服这些问题的方法不在于合成新的抗癌药物，而在于寻找合适的药物输送策略。在过去的几十年中，已经开发了各种输送系统，包括前药、配体设计和纳米载体，旨在提高这些新型金属药物的性能。
